← Leaderboards
Bradley J Backes
Metafold Therapeutics, Inc.
$3,258,304
Attributed
$4,932,631
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $710.2K · FY2009–22$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$4,932,631 · 7
By mechanism
R01$2,511,490 · 1
P01$1,463,292 · 1
R41$773,073 · 4
R43$184,776 · 1
Top collaborators
- Dustin J Maly5 shared
- Feroz R Papa5 shared
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisDesignPharmaceutical PreparationsProgramsPathway InteractionsSignal TransductionEndoplasmic ReticulumRna SplicingEndoplasmic Reticulum StressProteinsResponsePhosphotransferasesSignal PathwayProtein FoldingMessenger RnaRibonucleasesSmall MoleculeOralCellsMediatingBaseDisease ProgressionGlycemic ControlAnimal Model
Grant awards (16)
Developing UPR inhibitory KIRAs into oral antidiabetic beta cell-sparing drugs$502,298
R01 · FY2022 · DK
Developing UPR inhibitory KIRAs into oral antidiabetic beta cell-sparing drugs$502,298
R01 · FY2021 · DK
Developing UPR inhibitory KIRAs into oral antidiabetic beta cell-sparing drugs$502,298
R01 · FY2020 · DK
Developing UPR inhibitory KIRAs into oral antidiabetic beta cell-sparing drugs$502,298
R01 · FY2019 · DK
Developing UPR inhibitory KIRAs into oral antidiabetic beta cell-sparing drugs$502,298
R01 · FY2018 · DK
IRE1 alpha inhibitors for Retinal Degenerative Diseases$73,151
R41 · FY2016 · EY · contact PI
Medicinal Chemistry/Sheppard$388,196
P01 · FY2015 · HL · contact PI
IRE1 alpha inhibitors for type 2 diabetes$199,611
R41 · FY2015 · DK · contact PI
IRE1 alpha inhibitors for Retinal Degenerative Diseases$122,403
R41 · FY2015 · EY · contact PI
Medicinal Chemistry/Sheppard$360,500
P01 · FY2014 · HL · contact PI
Medicinal Chemistry/Sheppard$349,081
P01 · FY2013 · HL · contact PI
Medicinal Chemistry/Sheppard$365,515
P01 · FY2012 · HL · contact PI
Inflammasome Inhibitors for Type 2 Diabetes$184,776
R43 · FY2012 · DK · contact PI
Developing UPR Modulators as Novel Therapeutics for Neurodegeneration$196,688
R41 · FY2011 · NS · contact PI
Cytoprotective Effects of UPR Modulators in ER Stress-Challenged beta-Cells$152,520
R41 · FY2009 · DK · contact PI
Cytoprotective Effects of UPR Modulators in ER Stress-Challenged beta-Cells$28,700
R41 · FY2009 · DK · contact PI